KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

Teva Pharmaceutical Industries (TEVA) Leases (2018 - 2026)

Teva Pharmaceutical Industries filings provide 12 years of Leases readings, the most recent being $335.0 million for Q1 2026.

  • On a quarterly basis, Leases fell 7.71% to $335.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $335.0 million, a 7.71% decrease, with the full-year FY2025 number at $345.0 million, down 5.99% from a year prior.
  • Leases hit $335.0 million in Q1 2026 for Teva Pharmaceutical Industries, down from $345.0 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $464.0 million in Q1 2022 to a low of $335.0 million in Q1 2026.
  • Median Leases over the past 5 years was $367.0 million (2024), compared with a mean of $387.2 million.
  • Biggest five-year swings in Leases: dropped 16.95% in 2022 and later changed 0.0% in 2025.
  • Teva Pharmaceutical Industries' Leases stood at $419.0 million in 2022, then decreased by 5.25% to $397.0 million in 2023, then fell by 7.56% to $367.0 million in 2024, then dropped by 5.99% to $345.0 million in 2025, then fell by 2.9% to $335.0 million in 2026.
  • The last three reported values for Leases were $335.0 million (Q1 2026), $345.0 million (Q4 2025), and $342.0 million (Q3 2025) per Business Quant data.